Animal Care expands U.S. presence with new partnership, securing an order of appr. USD 66,000

Scandinavian ChemoTech’s Animal Care is excited to announce a partnership with one of the largest veterinary groups in the U.S., marking a major step in expanding the footprint of vetIQure™. For the first time, multiple locations within a single group are simultaneously adopting our advanced TSE technology.

This specialty and emergency clinic group, staffed by board-certified and residency-trained veterinarians, has integrated vetIQure™ TSE to enhance oncology treatments. The technology offers a safe, effective, and minimally invasive tumor care solution, preserving healthy tissue while improving outcomes.

By adopting vetIQure™ TSE, the clinics provide pet owners with advanced treatment options, personalized support, and greater confidence in their decisions.

“We are delighted to bring the VetIQure™ TSE system to more veterinary clinics across the U.S., expanding access to innovative treatment options for pets and their families,” said Mohan S. Frick, CEO, Scandinavian ChemoTech AB. “This partnership marks a significant milestone in Scandinavian ChemoTech Animal Care’s mission to transform veterinary oncology care and grow our presence in the U.S. market.”

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-04-2025 09:15 CET.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Certified Adviser: Redeye AB

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.